Recent Investment Analysts’ Ratings Changes for Trevena (TRVN)

Trevena (NASDAQ: TRVN) recently received a number of ratings updates from brokerages and research firms:

  • 3/22/2017 – Trevena had its “buy” rating reaffirmed by analysts at Cowen and Company. They now have a $13.00 price target on the stock. They wrote, “TRVN reported 4Q16 results.””
  • 3/22/2017 – Trevena had its “buy” rating reaffirmed by analysts at Oppenheimer Holdings Inc..
  • 3/14/2017 – Trevena was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company’s product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania. “
  • 3/14/2017 – Trevena was given a new $10.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 3/11/2017 – Trevena had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.
  • 3/11/2017 – Trevena was given a new $8.00 price target on by analysts at FBR & Co. They now have a “buy” rating on the stock.
  • 2/25/2017 – Trevena was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company’s product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania. “
  • 2/23/2017 – Trevena had its price target lowered by analysts at HC Wainwright from $11.00 to $8.00. They now have a “buy” rating on the stock.
  • 2/23/2017 – Trevena had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $10.00 price target on the stock, down previously from $13.00.
  • 2/22/2017 – Trevena was given a new $9.00 price target on by analysts at Roth Capital. They now have a “buy” rating on the stock.
  • 2/22/2017 – Trevena had its “outperform” rating reaffirmed by analysts at FBR & Co. They now have a $8.00 price target on the stock, down previously from $13.00.
  • 2/22/2017 – Trevena had its “positive” rating reaffirmed by analysts at Aegis. They now have a $14.00 price target on the stock.
  • 2/21/2017 – Trevena had its “buy” rating reaffirmed by analysts at Cowen and Company. They wrote, “TRVN reported top-line results from the pivotal Ph3 APOLLO trials of oliceridine in.””
  • 2/16/2017 – Trevena had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $11.00 price target on the stock.
  • 2/10/2017 – Trevena had its “buy” rating reaffirmed by analysts at Jefferies Group LLC.
  • 2/2/2017 – Trevena is now covered by analysts at Ladenburg Thalmann Financial Services. They set a “buy” rating and a $15.00 price target on the stock.

Trevena Inc (NASDAQ:TRVN) opened at 3.55 on Monday. Trevena Inc has a 1-year low of $3.26 and a 1-year high of $9.49. The stock’s market capitalization is $202.81 million. The company’s 50 day moving average is $5.00 and its 200-day moving average is $5.83.

Trevena (NASDAQ:TRVN) last posted its quarterly earnings data on Wednesday, March 8th. The biopharmaceutical company reported ($0.67) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by $0.05. Trevena had a negative net margin of 841.00% and a negative return on equity of 66.50%. During the same quarter in the previous year, the company earned ($0.30) EPS. Analysts forecast that Trevena Inc will post ($1.67) earnings per share for the current fiscal year.

Trevena Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250.

5 Day Chart for NASDAQ:TRVN

Receive News & Ratings for Trevena Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.